Aptose Biosciences Inc. (APTO) Reaches $3.87 After 3.00% Down Move; Last Week Core-Mark Holding Company, Inc. (CORE) Analysts

June 14, 2018 - By Matthew Harris

Core-Mark Holding Company, Inc. (NASDAQ:CORE) Logo

The stock of Aptose Biosciences Inc. (NASDAQ:APTO) is a huge mover today! The stock decreased 3.25% or $0.13 during the last trading session, reaching $3.87. About 679,271 shares traded or 88.46% up from the average. Aptose Biosciences Inc. (NASDAQ:APTO) has risen 252.94% since June 14, 2017 and is uptrending. It has outperformed by 240.37% the S&P500. Some Historical APTO News: ; 07/05/2018 – APTOSE BIOSCIENCES INC – EXERCISES EARLY OPTION FOR CG-806 LICENSE FROM CRYSTALGENOMICS; 16/04/2018 – Aptose Presents New Preclinical Data on CG’806 Pan-FLT3/ Pan-BTK Inhibitor at 2018 AACR Annual Meeting; 07/05/2018 – Aptose Biosciences Expects to Submit IND in Late 2018 and Initiate Clinical Trials Immediately Thereafter; 16/04/2018 – OHSU and Aptose Present New CG’806 Preclinical Data at 2018 AACR Annual Meeting; 25/04/2018 – Aptose Biosciences Board of Directors Now Includes Seven Members; 07/05/2018 – Aptose Exercises Early Option for CG-806 License From CrystalGenomics; 25/04/2018 – APTOSE BIOSCIENCES INC – APTOSE’S BOARD OF DIRECTORS NOW INCLUDES SEVEN MEMBERS; 10/05/2018 – Aptose Biosciences 1Q EPS 23c; 17/05/2018 – Aptose to Present New CG’806 Data at the 23rd Congress of the European Hematology Association; 07/05/2018 – APTOSE BIOSCIENCES INC – CO OWNS GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE CG-806 FOR ALL INDICATIONS OUTSIDE OF KOREA AND CHINA – LICENSED TERRITORYThe move comes after 8 months negative chart setup for the $129.55 million company. It was reported on Jun, 14 by Barchart.com. We have $3.75 PT which if reached, will make NASDAQ:APTO worth $3.89M less.

Among 8 analysts covering Core-Mark Holding Company (NASDAQ:CORE), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Core-Mark Holding Company had 25 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Wednesday, June 21 by Jefferies. Raymond James maintained Core-Mark Holding Company, Inc. (NASDAQ:CORE) rating on Tuesday, August 30. Raymond James has “Outperform” rating and $46 target. The firm has “Hold” rating given on Friday, January 5 by Stephens. The firm has “Hold” rating by Jefferies given on Thursday, October 12. The company was maintained on Wednesday, August 9 by Raymond James. Stephens maintained the stock with “Hold” rating in Friday, March 2 report. The stock of Core-Mark Holding Company, Inc. (NASDAQ:CORE) earned “Buy” rating by Raymond James on Friday, January 5. The rating was maintained by Jefferies with “Hold” on Thursday, August 3. Jefferies maintained the stock with “Hold” rating in Monday, January 29 report. BMO Capital Markets maintained Core-Mark Holding Company, Inc. (NASDAQ:CORE) rating on Friday, March 2. BMO Capital Markets has “Market Perform” rating and $23 target. See Core-Mark Holding Company, Inc. (NASDAQ:CORE) latest ratings:

09/05/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $23 New Target: $21 Maintain
02/03/2018 Broker: Stephens Rating: Hold New Target: $23.0 Maintain
01/03/2018 Broker: Jefferies Rating: Hold New Target: $23.0 Maintain
02/03/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $26 New Target: $23 Maintain
29/01/2018 Broker: Jefferies Rating: Hold New Target: $26.0 Maintain
05/01/2018 Broker: Raymond James Rating: Buy Upgrade
05/01/2018 Broker: Stephens Rating: Hold Downgrade
05/01/2018 Broker: BMO Capital Markets Rating: Hold New Target: $33.0 Initiate
04/01/2018 Broker: William Blair Rating: Outperform Initiates Coverage On

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company has market cap of $129.55 million. The Company’s lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. It currently has negative earnings. The firm has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.

Analysts await Aptose Biosciences Inc. (NASDAQ:APTO) to report earnings on August, 14. They expect $-0.17 EPS, down 54.55% or $0.06 from last year’s $-0.11 per share. After $-0.23 actual EPS reported by Aptose Biosciences Inc. for the previous quarter, Wall Street now forecasts -26.09% EPS growth.

More notable recent Aptose Biosciences Inc. (NASDAQ:APTO) news were published by: Benzinga.com which released: “Benzinga Pro’s 5 Stocks To Watch Today” on June 14, 2018, also Benzinga.com with their article: “23 Stocks Moving In Thursday’s Pre-Market Session” published on June 14, 2018, Seekingalpha.com published: “On The Move: Aptose Biosciences” on May 25, 2018. More interesting news about Aptose Biosciences Inc. (NASDAQ:APTO) were released by: Nasdaq.com and their article: “Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253” published on June 04, 2018 as well as Globenewswire.com‘s news article titled: “Aptose Biosciences Announces Results of Annual Meeting of Shareholders” with publication date: June 05, 2018.

Among 5 analysts covering Aptose Biosciences (NASDAQ:APTO), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Aptose Biosciences had 20 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, November 15. The rating was initiated by H.C. Wainwright with “Hold” on Thursday, June 8. The stock of Aptose Biosciences Inc. (NASDAQ:APTO) has “Buy” rating given on Tuesday, June 5 by Roth Capital. TH Capital downgraded the shares of APTO in report on Friday, November 20 to “Neutral” rating. Roth Capital maintained Aptose Biosciences Inc. (NASDAQ:APTO) on Monday, April 16 with “Buy” rating. On Wednesday, March 28 the stock rating was maintained by H.C. Wainwright with “Buy”. The stock of Aptose Biosciences Inc. (NASDAQ:APTO) has “Outperform” rating given on Wednesday, November 16 by RBC Capital Markets. The firm earned “Outperform” rating on Wednesday, November 11 by RBC Capital Markets. The firm has “Buy” rating by Roth Capital given on Monday, June 13. The rating was maintained by H.C. Wainwright with “Buy” on Monday, October 30.

Since March 14, 2018, it had 5 buys, and 1 sale for $367,342 activity. BOOTH STUART W bought $91,470 worth of stock or 5,000 shares. COLTER GARY F bought $91,700 worth of Core-Mark Holding Company, Inc. (NASDAQ:CORE) on Tuesday, May 22. $54,960 worth of Core-Mark Holding Company, Inc. (NASDAQ:CORE) shares were bought by Tepner Harvey L. ALLEN ROBERT A also bought $92,200 worth of Core-Mark Holding Company, Inc. (NASDAQ:CORE) shares. Rolheiser Eric had sold 6,471 shares worth $145,598 on Wednesday, March 14. Shares for $182,610 were bought by THORNTON RANDOLPH I.

Investors sentiment decreased to 1.05 in 2018 Q1. Its down 0.07, from 1.12 in 2017Q4. It fall, as 18 investors sold Core-Mark Holding Company, Inc. shares while 45 reduced holdings. 22 funds opened positions while 44 raised stakes. 40.68 million shares or 2.18% less from 41.59 million shares in 2017Q4 were reported. State Of Alaska Department Of Revenue invested in 0.01% or 14,849 shares. Teacher Retirement Systems Of Texas holds 0% or 10,228 shares. Royal National Bank Of Canada, a Ontario – Canada-based fund reported 869,054 shares. Pub Employees Retirement Association Of Colorado holds 0% of its portfolio in Core-Mark Holding Company, Inc. (NASDAQ:CORE) for 9,279 shares. 14,285 are owned by Barclays Public Limited Company. Loomis Sayles And Limited Partnership invested in 366,274 shares. Smithfield Trust invested 0.01% in Core-Mark Holding Company, Inc. (NASDAQ:CORE). Alliancebernstein Ltd Partnership has 69,772 shares. Frontier Mgmt Lc invested in 163,078 shares or 0.03% of the stock. Pinebridge Limited Partnership owns 79,251 shares or 0.04% of their US portfolio. California Pub Employees Retirement System owns 0% invested in Core-Mark Holding Company, Inc. (NASDAQ:CORE) for 20,698 shares. American Interest Gp stated it has 0% of its portfolio in Core-Mark Holding Company, Inc. (NASDAQ:CORE). Natixis Advsrs Lp has 0.02% invested in Core-Mark Holding Company, Inc. (NASDAQ:CORE) for 85,817 shares. Stone Ridge Asset Management Ltd Limited Liability Company reported 25,758 shares stake. Parametric Portfolio Assocs Ltd Company accumulated 137,090 shares.

The stock increased 2.49% or $0.5 during the last trading session, reaching $20.59. About 83,890 shares traded. Core-Mark Holding Company, Inc. (NASDAQ:CORE) has declined 46.82% since June 14, 2017 and is downtrending. It has underperformed by 59.39% the S&P500. Some Historical CORE News: ; 08/05/2018 – CORE-MARK HOLDING COMPANY INC CORE.O FY2018 SHR VIEW $1.19, REV VIEW $16.66 BLN — THOMSON REUTERS l/B/E/S; 08/05/2018 – Core-Mark 1Q Adjusted EBITDA Increased 24% to $24.3M; 08/05/2018 – CORE-MARK 1Q EPS EX-LIFO EXPENSE 7C, EST. 8C; 08/05/2018 – CORE-MARK HOLDING COMPANY INC CORE.O SEES FY 2018 SHR $1.13 TO $1.29 EXCLUDING ITEMS; 08/05/2018 – Core-Mark 1Q Loss $1.3M; 08/05/2018 – CORE-MARK HOLDING COMPANY INC CORE.O SEES FY 2018 SALES $16.6 BLN TO $16.8 BLN; 11/04/2018 – Core-Mark Closes Above 50-Day Moving Average: Technicals; 23/05/2018 – Core-Mark Roadshow Set By Loop Capital Markets for May. 30; 08/05/2018 – Core-Mark 1Q Loss/Shr 3c; 08/05/2018 – Core-Mark Sees 2018 EPS 84c-EPS $1.00

Core-Mark Holding Company, Inc. (NASDAQ:CORE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: